In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.
Browsing: lung cancer
Scientists have discovered a key molecular player in lung cancer, which could be used to tackle the disease.
Findings demonstrate the potential of T2-weighted MRI in dual imaging and radiotherapy systems that aim to image and treat tumors simultaneously.
Lung cancer risk assessment could be improved over existing guidelines by a four-protein biomarker blood test.
A team of researchers have developed the first comprehensive atlas of lung tumor cells.
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
Find out more about the utility of clinical characteristics in the selection of patients with advanced NSCLC as potential candidates for single-agent anti-PD-1/PD-L1 immunotherapy in this open access Future Oncology review article.
Results of the KEYNOTE-042 study have demonstrated pembrolizumab to be more effective in most patients with the most common form of lung cancer, in comparison to the current standard-of-care, namely, chemotherapy.
A preliminary report has revealed that a blood test could be used as a tool to detect early-stage lung cancer in patients.
Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer
Discover the case of nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer in this article from the impactful journal Immunotherapy.
Researchers have devised a method that allows them to personalize the lung cancer screening decision for every patient; the tool is termed Lung Decision Precision.